Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes

NCT01602003 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

425

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: LC15-0444 25mg bid
DRUG: LC15-0444 50mg qd
DRUG: Sitagliptin 100mg qd

Sponsor

LG Life Sciences